Dear Therapeutic Provider:

Effective immediately, sotrovimab is no longer authorized for use in Texas. Results from studies that are used to assess the susceptibility of viral variants to monoclonal antibodies suggest that the efficacy of sotrovimab is reduced against the BA.2 variant. The FDA updated Fact Sheet for sotrovimab on March 25, 2022 to reflect new data using authentic live BA.2 virus. Because the variant percentage in the region that contains Texas (Region 6) is now over 50% BA.2 variant, sotrovimab is no longer authorized for use in Texas and surrounding states. Please visit HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) for important updates about therapeutics.

There are several other therapies – Paxlovid, Veklury (remdesivir), bebtelovimab, and Lagevrio (molnupiravir) – that are expected to be effective against the BA.2 sub-variant, and that are authorized or approved to treat certain patients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease, including hospitalization or death. Health care providers should assess whether these treatments are right for their patients and can refer to the recently-updated NIH Guidelines for Therapeutic Management of Nonhospitalized Adults With COVID-19. Please see the US HHS Therapeutic locator for locations with these medications.

Sotrovimab administered after 4/5/2022 must be reported as a medication error to FDA MedWatch online at https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program or by faxing or mailing form 3500 (call 1-800-FDA-1088 to request the reporting form).

Please email therapeutics@dshs.texas.gov to request bebtelovimab in multiples of ten (10). Make sure your reporting of administered and on-hand therapeutics is current. Emailed requests received by Thursdays at 5pm will be allocated the following week. US HHS and DSHS will transition in coming weeks to allow providers to place requests for therapeutics in HPOP. DSHS will provided additional information about the change in coming communications.

Visit DSHS Information for COVID-19 Therapeutics Providers for current information.